JP2007332155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007332155A5 JP2007332155A5 JP2007211802A JP2007211802A JP2007332155A5 JP 2007332155 A5 JP2007332155 A5 JP 2007332155A5 JP 2007211802 A JP2007211802 A JP 2007211802A JP 2007211802 A JP2007211802 A JP 2007211802A JP 2007332155 A5 JP2007332155 A5 JP 2007332155A5
- Authority
- JP
- Japan
- Prior art keywords
- polysaccharide
- botulinum toxin
- pharmaceutical composition
- neurotoxin
- clostridial neurotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims 9
- 229920001282 polysaccharide Polymers 0.000 claims 9
- 239000005017 polysaccharide Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108030001720 Bontoxilysin Proteins 0.000 claims 5
- 229940053031 botulinum toxin Drugs 0.000 claims 5
- 108010055044 Tetanus Toxin Proteins 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims 3
- 101710138657 Neurotoxin Proteins 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 229940050526 hydroxyethylstarch Drugs 0.000 claims 3
- 239000002581 neurotoxin Substances 0.000 claims 3
- 231100000618 neurotoxin Toxicity 0.000 claims 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 2
- 229940094657 botulinum toxin type a Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 238000004925 denaturation Methods 0.000 claims 1
- 230000036425 denaturation Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50014700A | 2000-02-08 | 2000-02-08 | |
| US09/500,147 | 2000-02-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004084590A Division JP4118830B2 (ja) | 2000-02-08 | 2004-03-23 | ボツリヌス毒素医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011160451A Division JP2011251988A (ja) | 2000-02-08 | 2011-07-22 | ボツリヌス毒素医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007332155A JP2007332155A (ja) | 2007-12-27 |
| JP2007332155A5 true JP2007332155A5 (enExample) | 2008-04-17 |
| JP5080902B2 JP5080902B2 (ja) | 2012-11-21 |
Family
ID=23988236
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557580A Pending JP2003522154A (ja) | 2000-02-08 | 2001-02-05 | ボツリヌス毒素医薬組成物 |
| JP2004084590A Expired - Lifetime JP4118830B2 (ja) | 2000-02-08 | 2004-03-23 | ボツリヌス毒素医薬組成物 |
| JP2005079801A Pending JP2005179375A (ja) | 2000-02-08 | 2005-03-18 | ボツリヌス毒素医薬組成物 |
| JP2005196335A Withdrawn JP2005336201A (ja) | 2000-02-08 | 2005-07-05 | ボツリヌス毒素医薬組成物 |
| JP2007211802A Expired - Lifetime JP5080902B2 (ja) | 2000-02-08 | 2007-08-15 | ボツリヌス毒素医薬組成物 |
| JP2011160451A Pending JP2011251988A (ja) | 2000-02-08 | 2011-07-22 | ボツリヌス毒素医薬組成物 |
| JP2011233808A Pending JP2012031194A (ja) | 2000-02-08 | 2011-10-25 | ボツリヌス毒素医薬組成物 |
Family Applications Before (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557580A Pending JP2003522154A (ja) | 2000-02-08 | 2001-02-05 | ボツリヌス毒素医薬組成物 |
| JP2004084590A Expired - Lifetime JP4118830B2 (ja) | 2000-02-08 | 2004-03-23 | ボツリヌス毒素医薬組成物 |
| JP2005079801A Pending JP2005179375A (ja) | 2000-02-08 | 2005-03-18 | ボツリヌス毒素医薬組成物 |
| JP2005196335A Withdrawn JP2005336201A (ja) | 2000-02-08 | 2005-07-05 | ボツリヌス毒素医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011160451A Pending JP2011251988A (ja) | 2000-02-08 | 2011-07-22 | ボツリヌス毒素医薬組成物 |
| JP2011233808A Pending JP2012031194A (ja) | 2000-02-08 | 2011-10-25 | ボツリヌス毒素医薬組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20020064536A1 (enExample) |
| EP (4) | EP1586329A1 (enExample) |
| JP (7) | JP2003522154A (enExample) |
| KR (3) | KR100753765B1 (enExample) |
| CN (2) | CN1258379C (enExample) |
| AR (1) | AR027391A1 (enExample) |
| AT (2) | ATE293988T1 (enExample) |
| AU (2) | AU3331501A (enExample) |
| BR (1) | BR0108173A (enExample) |
| CA (3) | CA2494241C (enExample) |
| CY (1) | CY1108007T1 (enExample) |
| DE (2) | DE60125986T3 (enExample) |
| DK (3) | DK1253932T3 (enExample) |
| ES (3) | ES2275992T5 (enExample) |
| MX (1) | MXPA02007519A (enExample) |
| NZ (2) | NZ530779A (enExample) |
| PT (3) | PT1253932E (enExample) |
| TW (2) | TWI317283B (enExample) |
| WO (1) | WO2001058472A2 (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US8632785B2 (en) * | 2000-02-08 | 2014-01-21 | Allergan, Inc. | Clostridial toxin pharmaceutical composition containing a gelatin fragment |
| CA2494241C (en) * | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| DE10035156A1 (de) * | 2000-07-19 | 2002-02-07 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Proteinkomplex als Vehikel für oral verfügbare Protein-Arzneimittel |
| US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
| DE10149030A1 (de) * | 2001-10-05 | 2003-04-10 | Viscum Ag | Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin |
| US7140371B2 (en) * | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
| EP1491205A4 (en) * | 2002-03-29 | 2007-04-25 | Chemo Sero Therapeut Res Inst | MEANS FOR THE TREATMENT OF HYPERMYOTONIA |
| US7691394B2 (en) | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| US7459164B2 (en) | 2002-05-28 | 2008-12-02 | Botulinum Toxin Research Associates, Inc. | Composition for therapeutic and cosmetic botulinum toxin |
| US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
| MXPA05006690A (es) * | 2002-12-20 | 2006-02-17 | Botulinum Toxin Res Ass Inc | Composiciones farmaceuticas de toxina botulinica mejoradas. |
| US20050008661A1 (en) * | 2003-03-31 | 2005-01-13 | Fereira Pamela J. | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| FR2855177B1 (fr) * | 2003-05-23 | 2005-07-08 | Raymond Robert | Composition contenant des acides nucleiques lyophilises en presence de collagene et de disaccharides |
| US7160699B2 (en) | 2003-09-25 | 2007-01-09 | Allergan, Inc. | Media for clostridium bacterium and processes for obtaining a clostridial toxin |
| US7148041B2 (en) * | 2003-09-25 | 2006-12-12 | Allergan, Inc. | Animal product free media and processes for obtaining a botulinum toxin |
| US7452697B2 (en) | 2003-09-25 | 2008-11-18 | Allergan, Inc. | Chromatographic method and system for purifying a botulinum toxin |
| US20100266638A1 (en) | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| US9078892B2 (en) * | 2004-02-26 | 2015-07-14 | Allergan, Inc. | Methods for treating pain and for treating a medication overuse disorder |
| US20050191321A1 (en) | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
| US7691381B2 (en) | 2004-04-15 | 2010-04-06 | Allergan, Inc. | Stabilized biodegradable neurotoxin implants |
| RU2255761C1 (ru) * | 2004-07-01 | 2005-07-10 | Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" | Препарат для лечения мышечных дистоний из токсина культуры clostridium botulinum и способ его получения |
| GB2416122A (en) † | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| BRPI0513850A (pt) | 2004-07-26 | 2008-05-20 | Merz Pharma Gmbh & Co Kgaa | composição terapêutica com uma neurotoxina botulìnica |
| EP2813239B1 (en) * | 2004-08-04 | 2017-03-22 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin A2 |
| US20080102090A1 (en) * | 2004-08-04 | 2008-05-01 | Naveed Panjwani | Pharmaceutical Compositon Containing Botulinum Neurotoxin A2 |
| WO2006073410A1 (en) * | 2005-01-03 | 2006-07-13 | Botulinum Toxin Research Associates, Inc. | Compositions, methods and devices for preparing less painful botulinum toxin formulations |
| US7838011B2 (en) | 2005-02-14 | 2010-11-23 | Pankaj Modi | Stabilized protein compositions for topical administration and methods of making same |
| US7727537B2 (en) | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
| BRPI0608249A2 (pt) * | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
| CN1930186A (zh) * | 2005-03-03 | 2007-03-14 | 阿勒根公司 | 为获得梭菌毒素的梭菌细菌培养基及方法 |
| US8926991B2 (en) * | 2005-06-14 | 2015-01-06 | Botulinum Toxin Research Associates, Inc. | Botulinum toxin and the treatment of primary disorders of mood and affect |
| US20230390368A1 (en) * | 2005-06-27 | 2023-12-07 | Revance Therapeutics, Inc. | Methods of Treating Cervical Dystonia in a Subject Having Underlying Condition(s) |
| US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| FR2889936B1 (fr) | 2005-09-01 | 2007-12-21 | Sod Conseils Rech Applic | Methode pour quantifier une neurotoxine cholinergique dans un echantillon |
| US7744904B1 (en) | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
| AU2013202329B2 (en) * | 2005-10-06 | 2016-04-14 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| WO2007044809A2 (en) * | 2005-10-11 | 2007-04-19 | Botulinum Toxin Research Associates, Inc. | Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use |
| CN100384993C (zh) * | 2005-11-02 | 2008-04-30 | 浙江大学 | 提高地衣芽孢杆菌zjuel31410弹性蛋白酶稳定性的方法 |
| FR2896693B1 (fr) * | 2006-01-27 | 2008-03-14 | Sod Conseils Rech Applic | Composition comprenant plusieurs toxines botuliques |
| DE102006019447A1 (de) * | 2006-04-24 | 2007-10-25 | Dressler, Dirk, Dr. | Markierung von Botulinum Toxin |
| US9175283B2 (en) | 2006-05-31 | 2015-11-03 | Genzyme Corporation | Use polysaccharides for promotion of enzymatic activity |
| FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
| FR2907680B1 (fr) | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
| FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| CN102988995A (zh) * | 2006-12-29 | 2013-03-27 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| JP2010529155A (ja) * | 2007-06-13 | 2010-08-26 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用 |
| CA2690773C (en) * | 2007-07-10 | 2013-09-17 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| US7473429B1 (en) * | 2007-07-27 | 2009-01-06 | Renfroe J Ben | Method for treatment of laminitis in animals |
| JP2009132686A (ja) * | 2007-10-26 | 2009-06-18 | Okayama Univ | ボツリヌス毒素由来のポリペプチド及びボツリヌス毒素の検出方法 |
| EP2072039A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| EP2072057A1 (en) | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Early administration of Botulinum toxin in the treatment of cerebrovascular event and spinal cord injury |
| US9107815B2 (en) | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
| US20100034854A1 (en) * | 2008-08-05 | 2010-02-11 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type B (150 KD) |
| WO2010016895A1 (en) * | 2008-08-05 | 2010-02-11 | Solstice Neurosciences, Inc. | Compositions of activated botulinum toxin type b |
| WO2010051039A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum toxin type b |
| WO2010051038A1 (en) * | 2008-11-03 | 2010-05-06 | Solstice Neurosciences, Inc. | Compositions of activated botulinum holotoxin type b (150 kd) |
| WO2010096134A1 (en) | 2008-12-04 | 2010-08-26 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
| KR20160103551A (ko) * | 2008-12-10 | 2016-09-01 | 알러간, 인코포레이티드 | 클로스트리디움 독소 약제학적 조성물 |
| HRP20180739T1 (hr) | 2008-12-31 | 2018-06-29 | Revance Therapeutics, Inc. | Injekcijske formulacije botulinskog toksina |
| US20100184685A1 (en) * | 2009-01-19 | 2010-07-22 | Zavala Jr Gerardo | Systems and methods for treating post- operative, acute, and chronic pain using an intra-muscular catheter administrated combination of a local anesthetic and a neurotoxin protein |
| EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| CA2766521C (en) | 2009-06-25 | 2020-07-21 | Revance Therapeutics, Inc. | Albumin-free botulinum toxin formulations |
| US8129139B2 (en) | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| WO2011112996A2 (en) * | 2010-03-12 | 2011-09-15 | Surmodics, Inc. | Injectable drug delivery system |
| JP5769379B2 (ja) * | 2010-03-17 | 2015-08-26 | グンゼ株式会社 | Ｄａｎｃｅタンパク質溶液 |
| CN103140205A (zh) * | 2010-10-06 | 2013-06-05 | 阿勒根公司 | 用于肉毒杆菌毒素的储藏和后续处理的系统 |
| EP2627318B1 (en) | 2010-10-12 | 2017-08-16 | Merz Pharma GmbH & Co. KGaA | Formulation suitable for stabilizing proteins, which is free of mammalian excipients |
| BR112013025256B1 (pt) * | 2011-03-31 | 2022-01-18 | Medy-Tox Inc | Preparação liofilizada farmacêutica |
| KR101135486B1 (ko) | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
| US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| CN104189891B (zh) * | 2014-08-15 | 2016-03-30 | 北京四环生物制药有限公司 | 一种不含人血清蛋白的重组人促红素制剂 |
| JP6798993B2 (ja) | 2014-12-23 | 2020-12-09 | メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト アウフ アクティーン | ボツリヌス毒素プレフィルド容器 |
| WO2016124213A1 (en) * | 2015-02-03 | 2016-08-11 | Merz Pharma Gmbh & Co. Kgaa | Botulinum toxin prefilled container |
| SG10202004337WA (en) | 2015-10-29 | 2020-06-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| WO2017188618A1 (en) * | 2016-04-26 | 2017-11-02 | Korea Prime Pharm Co., Ltd. | A novel composition comprising botulinum toxin |
| EP4026532B1 (en) * | 2016-05-27 | 2025-11-26 | Ipsen Biopharm Limited | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine |
| WO2018038585A1 (ko) * | 2016-08-26 | 2018-03-01 | 주식회사 에이비바이오 | 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법 |
| WO2018038301A1 (en) * | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| HUE046449T2 (hu) | 2016-09-13 | 2020-03-30 | Allergan Inc | Stabilizált, nem fehérje eredetû, clostridiális toxin készítmények |
| WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
| KR20190038292A (ko) * | 2017-09-29 | 2019-04-08 | 한국프라임제약주식회사 | 효능 지속시간이 연장된 보툴리눔 독소 조성물 |
| KR102657046B1 (ko) * | 2017-11-17 | 2024-04-15 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 이온 교환 물질을 갖춘 주사기 조립체 |
| KR102063475B1 (ko) * | 2018-02-22 | 2020-01-09 | 주식회사 에이비바이오 | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 |
| WO2020111852A1 (ko) | 2018-11-30 | 2020-06-04 | 주식회사 휴온스글로벌 | 보툴리눔 독소의 안정화 액상 조성물 |
| KR102259423B1 (ko) * | 2018-11-30 | 2021-06-02 | 주식회사 휴온스바이오파마 | 보툴리눔 독소의 안정화 액상 조성물 |
| KR20220140711A (ko) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법 |
| KR102404217B1 (ko) * | 2020-04-08 | 2022-06-02 | (주)메디톡스 | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 |
| WO2021206360A1 (ko) * | 2020-04-08 | 2021-10-14 | (주)메디톡스 | 토출 속도 조절이 용이하고 안정한 보툴리눔 독소 사전충전된 주사기 제형 |
| CN111675754A (zh) * | 2020-05-19 | 2020-09-18 | 四川一埃科技有限公司 | 一种肉毒毒素蛋白晶体结构及晶体制备方法和解析方法 |
| KR20230145053A (ko) | 2021-01-12 | 2023-10-17 | 듀렉트 코퍼레이션 | 지속 방출 약물 전달 시스템 및 관련 방법 |
| KR20250003215A (ko) | 2023-06-30 | 2025-01-07 | 주식회사 휴온스바이오파마 | 폴리솔베이트 20 및 세린을 포함하는 보툴리눔 독소의 안정화 액상 조성물 |
| WO2025059665A1 (en) | 2023-09-15 | 2025-03-20 | Revance Therapeutics, Inc. | Serial treatment with botulinum toxin for cervical dystonia |
| WO2025064729A1 (en) | 2023-09-19 | 2025-03-27 | Revance Therapeutics, Inc. | Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance |
| CN118697853B (zh) * | 2024-06-27 | 2025-05-02 | 河北封章生物科技有限公司 | 一种稳定性提高的肉毒素制剂 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5625041A (en) * | 1990-09-12 | 1997-04-29 | Delta Biotechnology Limited | Purification of proteins |
| US3269912A (en) * | 1963-04-08 | 1966-08-30 | Boehringer & Soehne Gmbh | Aluminum oxide depot vaccines |
| US3758382A (en) * | 1968-07-26 | 1973-09-11 | Us Navy | Ve agent process of freezing blood using a hydroxyalkyl starch as cryoprotecti |
| GB1514720A (en) * | 1974-10-07 | 1978-06-21 | Secr Defence | Preparation of hydroxyethyl starch |
| DE2457047C3 (de) * | 1974-12-03 | 1979-10-31 | Behringwerke Ag, 3550 Marburg | Verfahren zur Herstellung eines Derivates der leichten Kette des Tetanustoxins, dessen Verwendung zur Tetanusprophylaxe |
| NZ199722A (en) * | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4391801A (en) * | 1981-10-29 | 1983-07-05 | Cutter Laboratories, Inc. | Plasma protein fraction substantially free of acetate ions |
| US4457916A (en) * | 1982-08-31 | 1984-07-03 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same |
| JPS5959625A (ja) * | 1982-09-28 | 1984-04-05 | Dainippon Pharmaceut Co Ltd | ガン壊死因子を安定化する方法 |
| HU188847B (en) * | 1983-02-22 | 1986-05-28 | Human Oltoanyagtermeloe Es Kutato Intezet,Hu | Process for producing liophylized combined vaccines |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| EP0150067A3 (en) * | 1984-01-23 | 1986-12-30 | Takeda Chemical Industries, Ltd. | Stable composition of gamma-interferon |
| JPS61161222A (ja) * | 1985-01-09 | 1986-07-21 | Takeda Chem Ind Ltd | γ型インタ−フエロンフラグメントの組成物 |
| JPS60258125A (ja) * | 1984-06-06 | 1985-12-20 | Hayashibara Biochem Lab Inc | 蛋白性生理活性物質を含有する水溶性乾燥物 |
| US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
| JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US4962091A (en) * | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
| DE3621828A1 (de) * | 1986-06-28 | 1988-01-14 | Biotest Pharma Gmbh | Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff |
| JPH0696536B2 (ja) * | 1988-02-26 | 1994-11-30 | 佐藤製薬株式会社 | 制酸剤含有内用懸濁液 |
| JP2849632B2 (ja) * | 1988-04-08 | 1999-01-20 | 社団法人北里研究所 | ワクチン製剤 |
| FR2630115B1 (fr) * | 1988-04-14 | 1994-10-28 | Merieux Inst | Procede de stabilisation des solutions d'albumine humaine et solution obtenue |
| FR2649991B2 (fr) † | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5919665A (en) * | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
| US5945098A (en) * | 1990-02-01 | 1999-08-31 | Baxter International Inc. | Stable intravenously-administrable immune globulin preparation |
| WO1991012718A1 (en) * | 1990-03-01 | 1991-09-05 | Agouron Pharmaceuticals, Inc. | Enhanced cryopreservation with thermal hysteresis peptide |
| US5401243A (en) * | 1990-08-21 | 1995-03-28 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
| JPH055065A (ja) * | 1990-08-30 | 1993-01-14 | Warner Lambert Co | 親水性ポリマー及びそれとは異なる親水性物質を含有する新規組成物 |
| US5695956A (en) * | 1990-11-26 | 1997-12-09 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Clostridium perfingens type a enterotoxin toxoid and methods of preparation and use as a vaccine and therapeutic agent |
| JP2916947B2 (ja) * | 1990-11-28 | 1999-07-05 | 興和株式会社 | Ｃｐｂ―ｉの安定化方法及び製剤組成物 |
| US5704297A (en) * | 1991-02-06 | 1998-01-06 | The Dupont Merck Pharmaceutical Company | Dry powder composition of hydroxyethyl starch suitable for reconstitution |
| CA2110899C (en) * | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
| WO1993000807A1 (en) * | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
| JPH0672891A (ja) * | 1992-08-31 | 1994-03-15 | Green Cross Corp:The | ヒト血清アルブミン含有製剤 |
| CA2138020C (en) * | 1992-06-23 | 1999-02-16 | Eric A. Johnson | Pharmaceutical composition containing botulinum b complex |
| US5445817A (en) * | 1992-08-21 | 1995-08-29 | The United States Of America As Represented By The Department Of Health And Human Services | Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines |
| US5728553A (en) * | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| EP0593176A3 (en) * | 1992-09-28 | 1995-03-01 | Wisconsin Alumni Res Found | Pharmaceutical compositions containing botulinum toxin and method of manufacture. |
| US5466672A (en) * | 1992-12-04 | 1995-11-14 | Ophidian Pharmaceuticals, Inc. | Therapeutic use of clostridium difficile toxin A |
| JP3007785B2 (ja) * | 1993-03-16 | 2000-02-07 | 旭化成工業株式会社 | トロンボモジュリン組成物およびその変性防止方法 |
| US5562907A (en) * | 1993-05-14 | 1996-10-08 | Arnon; Stephen S. | Method to prevent side-effects and insensitivity to the therapeutic uses of toxins |
| CN1102851C (zh) * | 1993-06-04 | 2003-03-12 | 生物时间公司 | 类血浆溶液 |
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| JP3533687B2 (ja) * | 1993-12-17 | 2004-05-31 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの脱色方法 |
| JP3684584B2 (ja) * | 1993-12-17 | 2005-08-17 | 三菱ウェルファーマ株式会社 | ヒト血清アルブミンの脱色方法 |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US5670484A (en) * | 1994-05-09 | 1997-09-23 | Binder; William J. | Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders |
| DE69526340T2 (de) * | 1994-05-09 | 2002-11-14 | William J. Binder | Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN |
| JPH07308199A (ja) † | 1994-05-18 | 1995-11-28 | Green Cross Corp:The | ヒト血清アルブミンの製造方法 |
| FI970867A7 (fi) * | 1994-08-04 | 1997-04-08 | Quadrant Drug Delivery Ltd | Kiinteät, annostelusysteemit hallittua vapautumista varten, joihin sys teemeihin molekyylit on sisällytetty ja menetelmät niiden valmistamise ksi |
| WO1996005222A1 (en) * | 1994-08-08 | 1996-02-22 | Wisconsin Alumni Research Foundation | Purification and pharmaceutical compositions containing type g botulinum neurotoxin |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| DE69627963T2 (de) * | 1995-06-06 | 2004-03-04 | Pearce, L. Bruce, Cambridge | Verbesserte zusammensetzungen und verfahren zur chemodenervation mit neurotoxinen |
| US5919463A (en) * | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
| JP3098401B2 (ja) * | 1995-07-12 | 2000-10-16 | 株式会社エルティーティー研究所 | 経鼻投与用製剤 |
| DE19538687A1 (de) * | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
| US5837265A (en) * | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
| ATE241695T1 (de) * | 1996-03-13 | 2003-06-15 | Delta Biotechnology Ltd | Gärungs-steuerungssysteme |
| US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
| US5908825A (en) * | 1997-01-09 | 1999-06-01 | University Of Maryland At Baltimore | Dosage composition for nasal delivery and method of use of the same |
| JPH10245400A (ja) * | 1997-02-28 | 1998-09-14 | Eiken Chem Co Ltd | トランスフェリンレセプターの安定化方法 |
| JPH10251161A (ja) * | 1997-03-11 | 1998-09-22 | Green Cross Corp:The | 浮腫治療効果増強剤 |
| US6210683B1 (en) * | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
| US6051239A (en) * | 1997-10-20 | 2000-04-18 | Thomas Jefferson University | Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| ES2179414T3 (es) * | 1997-11-22 | 2003-01-16 | Roche Diagnostics Gmbh | Procedimiento mejorado de estabilizacion de proteinas. |
| US6346519B1 (en) * | 1998-09-09 | 2002-02-12 | Advanced Medical Instruments | Method and composition for treating arthritis |
| TW574036B (en) * | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6113915A (en) * | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6337075B1 (en) * | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
| CA2494241C (en) * | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| JP2003009897A (ja) * | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
| MXPA01011542A (es) * | 2001-11-13 | 2003-05-22 | Alcon Inc | Regeneracion del cartilago articular da°ado por la osteoartritis de grado i y ii, mediante la aplicacion intra-articular de una mezcla de hialuronato de sodio y de condroitin sulfato en un vehiculo de gel. |
-
2001
- 2001-02-05 CA CA2494241A patent/CA2494241C/en not_active Expired - Fee Related
- 2001-02-05 CN CNB018046592A patent/CN1258379C/zh not_active Expired - Fee Related
- 2001-02-05 EP EP05006664A patent/EP1586329A1/en not_active Ceased
- 2001-02-05 DK DK01905436T patent/DK1253932T3/da active
- 2001-02-05 PT PT01905436T patent/PT1253932E/pt unknown
- 2001-02-05 AT AT01905436T patent/ATE293988T1/de active
- 2001-02-05 PT PT04029089T patent/PT1514556E/pt unknown
- 2001-02-05 EP EP03025104A patent/EP1398038B2/en not_active Expired - Lifetime
- 2001-02-05 NZ NZ530779A patent/NZ530779A/en not_active IP Right Cessation
- 2001-02-05 CA CA002400318A patent/CA2400318C/en not_active Expired - Fee Related
- 2001-02-05 DE DE60125986T patent/DE60125986T3/de not_active Expired - Lifetime
- 2001-02-05 JP JP2001557580A patent/JP2003522154A/ja active Pending
- 2001-02-05 DK DK04029089.2T patent/DK1514556T3/da active
- 2001-02-05 BR BR0108173-0A patent/BR0108173A/pt not_active IP Right Cessation
- 2001-02-05 KR KR1020027010146A patent/KR100753765B1/ko not_active Expired - Lifetime
- 2001-02-05 WO PCT/US2001/003641 patent/WO2001058472A2/en not_active Ceased
- 2001-02-05 DE DE60110372T patent/DE60110372T2/de not_active Expired - Lifetime
- 2001-02-05 MX MXPA02007519A patent/MXPA02007519A/es active IP Right Grant
- 2001-02-05 DK DK03025104.5T patent/DK1398038T4/da active
- 2001-02-05 EP EP04029089A patent/EP1514556B1/en not_active Expired - Lifetime
- 2001-02-05 NZ NZ520201A patent/NZ520201A/en not_active IP Right Cessation
- 2001-02-05 EP EP01905436A patent/EP1253932B1/en not_active Expired - Lifetime
- 2001-02-05 AU AU3331501A patent/AU3331501A/xx active Pending
- 2001-02-05 PT PT03025104T patent/PT1398038E/pt unknown
- 2001-02-05 CA CA002478621A patent/CA2478621C/en not_active Expired - Lifetime
- 2001-02-05 ES ES03025104T patent/ES2275992T5/es not_active Expired - Lifetime
- 2001-02-05 AT AT04029089T patent/ATE519494T1/de active
- 2001-02-05 ES ES01905436T patent/ES2237551T3/es not_active Expired - Lifetime
- 2001-02-05 CN CNB2004100117577A patent/CN1331532C/zh not_active Expired - Fee Related
- 2001-02-05 ES ES04029089T patent/ES2368061T3/es not_active Expired - Lifetime
- 2001-02-05 AU AU2001233315A patent/AU2001233315B2/en not_active Ceased
- 2001-02-06 TW TW095148526A patent/TWI317283B/zh not_active IP Right Cessation
- 2001-02-06 TW TW090102480A patent/TWI282739B/zh not_active IP Right Cessation
- 2001-02-08 AR ARP010100574A patent/AR027391A1/es not_active Application Discontinuation
-
2002
- 2002-01-14 US US10/047,058 patent/US20020064536A1/en not_active Abandoned
-
2004
- 2004-03-23 JP JP2004084590A patent/JP4118830B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-18 JP JP2005079801A patent/JP2005179375A/ja active Pending
- 2005-07-05 JP JP2005196335A patent/JP2005336201A/ja not_active Withdrawn
-
2006
- 2006-03-14 KR KR1020060023656A patent/KR100665469B1/ko not_active Expired - Fee Related
- 2006-07-04 KR KR1020060062380A patent/KR100799400B1/ko not_active Expired - Fee Related
-
2007
- 2007-03-26 CY CY20071100420T patent/CY1108007T1/el unknown
- 2007-08-15 JP JP2007211802A patent/JP5080902B2/ja not_active Expired - Lifetime
-
2008
- 2008-04-25 US US12/109,486 patent/US20080213315A1/en not_active Abandoned
-
2011
- 2011-07-22 JP JP2011160451A patent/JP2011251988A/ja active Pending
- 2011-10-25 JP JP2011233808A patent/JP2012031194A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007332155A5 (enExample) | ||
| JP2003522154A5 (enExample) | ||
| US20240382571A1 (en) | Albumin-Free Botulinum Toxin Formulations | |
| CN109925284A (zh) | 肉毒杆菌毒素冻干制剂 | |
| JP2008535819A5 (enExample) | ||
| IL308091A (en) | Stabilized Clostridium toxin preparations without protein | |
| JP2012531442A5 (enExample) | ||
| JP2015231997A5 (enExample) | ||
| JP2018531984A5 (enExample) | ||
| CN104056250A (zh) | 脂肽组合物和相关方法 | |
| CN102746372B (zh) | 一种细胞外基质冷冻干燥保护液及其使用方法 | |
| JP2019512012A5 (enExample) | ||
| JP2017510585A5 (enExample) | ||
| BRPI0514411B1 (pt) | Formulação, e, método de produzir uma formulação | |
| RU2012122793A (ru) | Композиция, способ и набор для альфа-1 ингибитора протеазы | |
| ES2749474T3 (es) | Agente farmacéutico estable y liofilizado que contiene nocatiacina | |
| CN116916894A (zh) | 可长期储存的肉毒杆菌毒素冻干制剂剂型 | |
| CN105056205A (zh) | 一种含硼替佐米的药物组合物及其制备方法 | |
| JP6857613B2 (ja) | タンパク質の安定化 | |
| JP2017533961A5 (enExample) | ||
| KR101932247B1 (ko) | 데옥시콜린산 또는 그의 염을 포함하는 조성물 및 효소의 안정화 방법 | |
| JP6179939B2 (ja) | 高濃度γグロブリン製剤の粘度低下方法 | |
| JP7423028B2 (ja) | ボルテゾミブを含有する凍結乾燥医薬組成物 | |
| CN101376022B (zh) | 含聚乙二醇降纤酶的药物组合物 | |
| JP2011256111A (ja) | 敗血症の予防及び治療剤 |